Synthesis of highly functionalized tetrahydropyridines with potential biological activity

Aleksandra Wasilewska,[a]* Franciszek Sączewski,[a]* Maria Gdaniec,[b] Anna Makowska,[a] and Patrick J. Bednarski[c]

[a] Department of Chemical Technology of Drugs, Medical University of Gdansk,
Al. Gen. J. Hallera 107, 80-416 Gdansk, Poland
[b] Faculty of Chemistry, Adam Mickiewicz University, Grunwaldzka 6, 60-870 Poznan, Poland
[c] Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy,
University of Greifswald, Friedrich Str. 17, 17487 Greifswald, Germany
*E-mail: alwas@gumed.edu.pl, saczew@gumed.edu.pl*

Abstract

It is found that 1,2-dihydropyridine derivatives: 6-aryl-2,3-dihydro-6a*H*-imidazo[1,2-*a*]pyrido-[1,2-*c*][1,3,5]triazin-5(6*H*)-ones and 3,6,7,8a-tetrahydro-2*H*-diimidazo[1,2-*c*:1',2'-*e*]pyrido-[1,2-*a*][1,3,5]triazine underwent Diels-Alder reactions with highly reactive azadienophiles: 4-phenyl-1,2,4-triazoline-3,5-dione and phthalazine-1,4-dione. The structures of the products were confirmed by IR, ^{1}H–^{13}C heterocorrelated 2D NMR spectra HSQC and HMBC, mass spectra as well as single crystal X-ray crystallography.

Keywords: 1,2-dihydropyridines, tetrahydropyridines, Diels-Alder reactions

Introduction

Imidazo[1,2-*a*]-1,3,5-triazines are of pronounced pharmacological interest as potent dihydrofolate reductase inhibitors,[1] A$_1$ adenosine receptor antagonists,[2] antiviral agents[3] and granulocyte colony-stimulating factor mimetics.[4] They have been shown to affect the circulatory system[5] and thrombocyte aggregation[6] as well as cause sedation and antinociception in mice.[7] Their cytotoxicity toward human cancer cell lines and antioxidant properties have also been studied.[8]

One of the synthetic routes toward this class of compounds consists of the reaction of 2-chloro-4,5-dihydroimidazole **1** with pyridine alone[9] or its mixture with a suitably substituted phenyl isocyanate[10] as depicted in Scheme 1.

Scheme 1

The products 3,6,7,8a-tetrahydro-2*H*-diimidazo[1,2-*c*:1',2'-*e*]pyrido[1,2-*a*][1,3,5]triazine **2** or 6-aryl-2,3-dihydro-6a*H*-imidazo[1,2-*a*]pyrido[1,2-*c*][1,3,5]triazin-5(6*H*)-ones **3**, respectively, contain a 1,2-dihydropyridine moiety that is expected to function as a diene and react (in a Diels-Alder fashion) with suitably chosen dienophiles to give rise to new heteropolycyclic ring systems with potential biological activity. The [2+4] cycloaddition between carbon dienophiles and *N*-protected 1,2-dihydropyridines,[11] 2(1*H*)-pyridones,[12] 2-methylene-1,2-dihydropyridines[13] and other related systems is a well-established method of obtaining isoquinuclidine skeleton. The latter is present in natural products (iboga alkaloids, dioscorine) with central nervous system action[14] and hypoglycemic properties[15] as well as various synthetic compounds of diverse pharmacological activity.[16] The aim of the present studies was to test the utility of **2** and **3** as dienes for Diels-Alder reactions and to evaluate the cycloaddition products for cytotoxic activities on human cancer cell lines.

Results and Discussion

As shown in numerous reports[11] on isoquinuclidine ring system synthesis 1,2-dihydropyridines are poorly reactive dienes, requiring elevated temperatures and long reaction times. These harsh reaction conditions seemed incompatible with compounds **2** or **3** that undergo rapid decomposition in solution at room temperature. This is especially true for **2**, which is unstable even in the solid state and must be prepared just before use. The poor reactivity of simple 1,2-dihydropyridine derivatives toward standard dienophiles may in some cases be overcome by the use of Lewis acid catalyst[17] (which is intended to lower the LUMO energy of the dienophile[18]). This strategy was assumed inefficient with respect to compounds **2** and **3** because their binding with a Lewis acid would probably result in formation of even poorer dienes. Indeed, we found that addition of **2** or **3** into an equimolar mixture of AlCl₃ and maleimide affords (after several hours) only the adducts of AlCl₃ with **2** or **3** accompanied by decomposition products. Therefore

another approach was needed and the use of highly reactive azadienophiles 4-phenyl-1,2,4-triazoline-3,5-dione **4** and 1,4-phthalazinedione **5** seemed particularly appealing. There are quite a few reports on the reactions of 2-pyridones or *N*-protected 1,2-dihydropyridines with 4-substituted 1,2,4-triazoline-3,5-diones[19] or **5**,[19c] however, only in one case[20] were pharmacological properties of the resultant cycloadducts, i.e. their CNS depressant and cardiotonic activities, seen.

The reactions of compounds **2** and **3** with 4-phenyl-1,2,4-triazoline-3,5-dione **4** were carried out at –20 °C by dropwise addition of dichloromethane solution of **4** to diene dissolved in the same solvent. The consumption of the dienophile (indicated by discharge of its intense red color) was instantaneous and afforded complex reaction mixtures from which cycloadducts **6–7h** were isolated in 20–50 % overall yields by a combination of extraction and chromatographic methods (Scheme 2).

7a R = H
7b R = *p*-CH$_3$
7c R = *m*-CH$_3$
7d R = 3,4-diCH$_3$
7e R = *p*-Cl
7f R = *m*-Cl
7g R = 3,4-diCl
7h R = *p*-OCH$_3$

9a R = CH$_3$
9b R = Cl

i = *o*-NO$_2$C$_6$H$_4$SO$_2$NHNH$_2$, Et$_3$N

Scheme 2

The structures of the products were confirmed by ^{1}H NMR, ^{13}C NMR, IR and mass spectra as well as elemental analysis. The IR spectra of **6** and **7a**–**h** exhibited absorption at about 1780 and 1720 cm^{-1} characteristic for the stretching vibrations of 1,2,4-triazolidine-3,5-dione carbonyl groups and at about 1665 cm^{-1} corresponding to C=N group. Absorptions from protons belonging to 2,3,5-triazabicyclo[2.2.2]oct-7-ene system were observed in the ^{1}H NMR spectra as a series of five well-resolved signals in the range of 4.5–7.2 ppm. Their assignment was based on ^{1}H–^{13}C heterocorrelated 2D NMR spectra HSQC and HMBC of **6** and **7e** as representatives of the group (see supplementary material).

The two olefinic protons appeared as a pair of triplet-like multiplets localized at 6.59 and 6.99 ppm in the spectrum of **6** and at about 6.5 and 7.2 ppm in the case of compounds of type **7**. The chemical shifts of doublets (J~5 Hz) corresponding to the bridgehead protons: 15H in **6** and 13H in **7** were also very close, equal to 6.3 and 6.4 ppm, respectively. The substantial difference concerned the position of a 2 Hz doublet representing the proton of the C–N bridge which appeared at 4.89 ppm in the spectrum of **6** and at 5.8–6 ppm in the spectra of compounds **7a**–**h**. The strong deshielding of proton H6a may be rationalized by the diamagnetic anisotropy of the neighboring phenyl ring. The same explanation should also account for the up-field shift of the bridgehead proton (H9 or H7 for **6** or **7** respectively) from 5.45 ppm in the spectrum of **6** to about 4.6–4.8 ppm in the spectra of **7a**–**h**. As indicated by molecular models, H7 proton of **7** is placed above the phenyl ring and thus experiences the shielding effect of a diamagnetic ring current.

The ^{13}C NMR spectra of the products were also consistent with the proposed structures **6** and **7a**–**h**. In the aliphatic region of **7a**–**h** spectra two signals of imidazoline carbon atoms C3 and C2 were found at about 45 and 51 ppm, respectively, followed by three resonance lines at 52, 62 and 67 ppm representing C7, C13 and C6a carbon atoms, respectively. The absorptions of the olefinic C15 and C16 atoms were observed at about 133 and 125 ppm. The two carbonyl groups of urazole moiety gave two distinct signals at 154 and 155 ppm, while C5=O and C14a=N carbons resonated at about 151 and 149 ppm, respectively.

An unexpected structure confirmation was provided by a mass spectrum of compound **7e** that exhibited intense fragment ions at *m/z*=227 and *m/z*=248 (the latter accompanied by a free-times less intense ion at *m/z*=250), arising from retro Diels-Alder dissociation of the undetectable molecular ion as depicted in Scheme 3.

Scheme 3

Finally, good quality crystals of **6** were obtained from benzene that allowed unequivocal structure determination by X-ray diffraction methods (Figure 1). Compound **6** crystallizes in centrosymmetric space group *C2/c* which means both enantiomers are present within the crystal lattice. The difficulties in obtaining efficient packing of large and irregularly shaped molecules of **6** are reflected by inclusion of the solvent (benzene and water) molecules into the crystal. The X-ray structure analysis revealed formation of an *endo* product and indicated that the dienophile addition had taken place from the more hindered face of **2**, that is the one containing H8a hydrogen atom. As a result, the H8a atom is oriented *exo* with respect to the olefinic bridge.


Figure 1. X-Ray structure of compound **6** showing atomic labels and displacement ellipsoids at the 50% probability level.

In the case of compounds **6**, **7a**, **7b** and **7h** only one stereoisomeric form of the cycloadduct was obtained whereas for **7c**–**g** (probably because of their higher chromatographic mobility) isolation of a minor amount of additional, more polar product became possible. The ^{1}H and ^{13}C NMR spectra of the two products shared the same basic features indicative for the presence of 2,3,5-triazabicyclo[2.2.2]oct-7-ene system, imidazoline moiety and two phenyl rings. Their mass spectra were identical, suggesting they were to each other stereoisomers. The most evident

difference in the ^{1}H NMR spectra of the products concerned the absorption of proton H6a, which was observed at about 6 ppm for the higher-yield stereoisomer while in the case of the lower-yield one was shifted up-field to 5.4 ppm. According to literature reports,[19b,21] the *endo*-protons belonging to bicyclo[2.2.2]oct-2-ene system and its aza counterparts are anisotropically shielded by the neighboring double bond. The above data allows one to conclude that the olefinic bridge and the H6a proton are oriented *exo* in the main product while *endo* in the minor one. To further explore this possibility the ROESY spectra of the two stereoisomers of compound **7e** were taken (Figure 2). In the spectrum of the lower-yield product two diagnostic cross-peaks corresponding to H6a–H16 (stronger) and H6a–H15 (weaker) couplings were observed (Figure 2b). In the case of the main product no evidence for spatial vicinity of H6a to protons H15 or H16 was found (Figure 2a).


Figure 2. a) The ROESY spectrum and the proposed structure of the higher-yield stereoisomer of compound **7e**. b) The ROESY spectrum and the proposed structure of the lower-yield stereoisomer of compound **7e**. The diagnostic cross-peaks are highlighted red.

In the next step reduction of the aliphatic double bond of compounds **6**, **7b** and **7e** as representatives of **6**–**7h** series was attempted. Although catalytic (palladium on carbon) hydrogenation proved unsuccessful, the desired transformation was easily achieved in mild conditions using diimide generated *in situ* from *o*-nitrobenzenesulfonylhydrazide in the presence

of triethylamine (Scheme 2).[22] Upon reduction of the C15=C16 double bond the absorption of proton H6a was shifted down-field by 0.35 ppm in the case of the lower-yield stereoisomer of **7e** while remained unchanged for the higher-yield one. These observations are in agreement with the reported[19b,21] influence of the olefinic bridge reduction on the chemical shifts of *endo* and *exo* protons belonging to bicyclo[2.2.2]oct-2-ene ring systems and further support our assignment of compounds' **7a–h** stereochemistry.

In contrast to their precursors, compounds **8**, **9a** and **9b** formed good quality crystals, especially when recrystallized from acetonitrile. The reduced form of the higher-yield stereoisomer of **7e** was obtained as a racemic compound, crystallizing in orthorombic space group *Pbca*. As evidenced earlier by ROESY experiments, the C15=C16 carbon bridge and H6a proton occupy the opposite sides of the molecule (Figure 3). Taking into account the stereochemistry of the transition state, the compound is *exo*. The twisting of the unsubstituted phenyl ring from the plane defined by urazole ring is substantially smaller than in the case of **6** which results in both C–H···O=C contacts of 2.310 and 2.452 Å being shorter than the sum of the van der Waals radii of oxygen and hydrogen atoms (1.52+1.2 Å).[23]


Figure 3. X-Ray structure of compound **9b** showing atomic labels and displacement ellipsoids at the 50% probability level.

To further explore the utility of compounds **2**, **3a–h** as dienes for Diels-Alder synthesis their reactions with phthalazine-1,4-dione **5** were studied. The green solution of **5** (obtained by vacuum filtration of the slurry resulting from oxidation of 2,3-dihydrophthalazine-1,4-dione **10** with lead tetraacetate in acetonitrile[24]) was added immediately to the cold solution of diene in CH$_2$Cl$_2$ and allowed to react (Scheme 4).

Chromatographic separation of thus obtained reaction mixtures afforded the desired cycloadducts only in the case of **3b** and **3g** while the other substrates gave intractable mixtures of products. When comparing the ^{1}H NMR spectra of adducts **11a** and **11b** with that of **7a–h** it can be seen that olefinic protons and the one belonging to C–N bridge hold almost the same chemical shifts, while absorptions corresponding to both bridgehead protons of **11a** and **11b** are strongly (by about 1 ppm) shifted down-field to 5.54 and 7.23 ppm for H7 and H16, respectively. Because of geometric reasons the bridgehead protons of **11a** and **11b** are more strongly influenced by

diamagnetic anisotropy of carbonyl groups than their counterparts belonging to **7a–h** derivatives. The mass spectrum of **11a** contains intense peaks at $m/z=212$ and $m/z=228$ that correspond to ions **A** and **B** resulting from retro Diels-Alder fragmentation of the molecular ion (Scheme 5). The above fragmentation pattern proves that **11a** and **11b** are indeed [4+2]cycloaddition products.

Scheme 4

Scheme 5

Table 1. IC$_{50}$ values (µM) ± S. D. in three human cancer cell lines as an average of 3–6 independent experiments

Compound[a]	Cell lines		
	LCLC-103H	A-427	5637
6	14.73 ± 2.70	>20	6.32 ± 4.07
7e	14.86 ± 2.37	>20	6.10 ± 2.83
7e'	9.61 ± 2.55	>20	8.88 ± 2.18
7g	15.82 ± 0.68	>20	>20
11a	15.57 ± 1.91	>20	16.49 ± 1.28
11b	13.82 ± 0.83	10.51 ± 0.83	3.05 ± 0.37

[a]Compounds that exhibited IC$_{50}$ < 20 µM and were considered active. **7e'** - The lower-yield stereoisomer of **7e**.

Screening for cytotoxic activity of Diels-Alder adducts **6**, **7a–h**, **11a–b** and reduced derivatives **8**, **9a–b** was performed with three human cancer cell lines: the LCLC-103H large cell lung cancer, the A-427 small cell lung cancer and the 5637 bladder cancer.[25] The results of the antiproliferation screen (Table 1) provide no clear conclusion about the structure activity relationship between phenyl ring substitution pattern of compounds **7a–h** and their cytotoxicity. It seems that chlorine atoms, particularly in the *para* position, are preferred. This may suggest that lipophlicity of tested compounds plays important role.

It should be emphasized that all the reduced cycloadducts, including those originating from **6** and **7e**, turned out to lack any antiproliferative activity. This indicates that the presence of the olefinic bridge is essential for the mechanism of action of compounds **6**, **7e**, **7g**, **11a** and **11b**. A possible explanation is that the double bond in question undergoes metabolic activation, for example epoxidation reaction, that affords derivatives able to alkylate nucleophilic targets within the tumor cell. This kind of metabolic activation has been proposed to explain the anti-cancer properties of acronycine and its derivatives containing 2*H*-pyran ring.[26]

Conclusions

The use of highly reactive azadienophiles: 4-phenyl-1,2,4-triazoline-3,5-dione and 1,4-phthalazinedione enabled us to obtain Diels-Alder cycloadducts of type **6**, **7** and **11** from 1,2-dihydropyridine derivatives of type **2** or **3**. Compounds **6**, **7e**, **7g**, **11a** and **11b** derived from Diels-Alder reactions showed moderate cytotoxicity toward human cancer cell lines: 5637 and LCLC-103H. The C=C double bond of 2,3,5-triazabicyclo[2.2.2]oct-7-en system present in the tested compounds appeared critical for their activity as its reduction afforded inactive derivatives.

Experimental Section

General. Melting points were measured on a Boëtius apparatus. The IR spectra were recorded in KBr pellets using Thermo Scientific Nicolet 380 FT-IR spectrometer. Nuclear magnetic resonance spectra were determined on Varian Gemini 200 or Varian Unity Plus 500 spectrometers. [1]H and ^{13}C chemical shifts were measured relative to the residual solvent signal at 7.26 ppm and 77.0 (CDCl$_3$) or 2.50 and 39.5 ppm (DMSO-d_6). Mass spectra were recorded on MAT95-Finnigan spectrometer operating at ionization potential of 70 eV. Phthalhydrazide **10** and phenyl isocyanates used in the studies were purchased from Alfa Aesar while 4-phenyl-1,2,4-triazoline-3,5-dione **4**, lead tetraacetate and 2-nitrobenzenesulfonyl chloride from Aldrich and used without further purification. 2-Chloro-4,5-dihydroimidazole hydrogen sulfate,[27] 3,6,7,8a-Tetrahydro-2*H*-diimidazo[1,2-*c*:1',2'-*e*]pyrido[1,2-*a*][1,3,5]triazine **2**,[9] 6-aryl-2,3-dihydro-6a*H*-imidazo[1,2-*a*]pyrido[1,2-*c*][1,3,5]triazin-5(6*H*)-ones:[10] **3a**, **3e**, **3f**, **3h**, *o*-

nitrobenzenesulfonylhydrazide,[28] phthalazine-1,4-dione **5**[24] were prepared according to literature methods.

Flash column chromatography was performed by using 230-400 mesh silica gel 60 purchased from Alfa Aesar, while the plates used to perform preparative thin layer chromatography were coated with silica gel 60 PF$_{254}$ containing gypsum supplied by Merck. Preparative thin layer chromatography was performed using Chromatotron apparatus (Harrison Research Inc. USA).


Figure 4. Numbering of atoms used to describe ^{1}H and ^{13}C NMR spectra of compounds **3b–d** and **3g**.

Preparation of 6-aryl-2,3-dihydro-6a*H*-imidazo[1,2-*a*]pyrido[1,2-*c*][1,3,5]triazin-5(6*H*)-ones: (3b–d) and (3g) was realized according to the procedure described in ref. 10 starting with 25 mmol (2.5 g) of **1**, 30 mmol of an appropriate aromatic isocyanate and 75 mmol (5.9 g, 6 ml) of pyridine.

6-(4-methylphenyl)-2,3-dihydro-6a*H*-imidazo[1,2-*a*]pyrido[1,2-*c*][1,3,5]triazin-5(6*H*)-one (3b). Yellow crystals from ethanol/water, yield 42%, 3 g, mp (dec): 163–164 °C; IR (v_{max}, cm^{-1}): 3062, 3032, 2967, 2877, 1692 (C=O), 1661 (C=N), 1588, 1466, 1372, 808. ^{1}H NMR (200 MHz, CDCl$_3$): δ_H 2.36 (3H, s, CH$_3$), 3.72–3.84 (1H, m, H3), 3.89–3.98 (2H, m, 2×H2), 4.08–4.22 (1H, m, H3'), 4.85 (1H, ddt, J = 10.2, 3.2, 1 Hz, H7), 5.14 (1H, ddd, J = 7.6, 5.9, 1 Hz, H9), 5.96 (1H, dddd, J = 10.2, 5.9, 1.7, 1 Hz, H8), 6.45 (1H, dd, J = 3.2, 1.7 Hz, H6a), 6.88 (dt, J = 7.6, 1 Hz, H10), 7.06 (2H, d, J = 8.4 Hz, aromat.), 7.20 (2H, d, J = 8.4 Hz, aromat.). ^{13}C NMR (50 MHz, CDCl$_3$): δ_C 20.5 (CH$_3$), 44.7 (C3), 51.5 (C2), 67.9 (C6a), 99.9 (C9), 112.9 (C7), 124.8 (C8), 125.2 (C10), 129.6, 129.8, 132.5, 138.1 (6C aromat.), 151.4 (C=N), 151.9 (C=O). Anal. Calcd for C$_{16}$H$_{16}$N$_4$O (280,32): C, 68.55; H, 5.75; N, 19.99%. Found: C, 68.48; H, 5.68; N, 20.11%

6-(3-methylphenyl)-2,3-dihydro-6a*H*-imidazo[1,2-*a*]pyrido[1,2-*c*][1,3,5]triazin-5(6*H*)-one (3c). Beige crystals from ethanol/water, yield 50%, 3.5 g, mp (dec.): 162–163 °C; IR (v_{max}, cm^{-1}) 3067, 3031, 2946, 2878, 1691 (C=O), 1662 (C=N), 1650, 1587, 1490, 1373, 1332, 769. ^{1}H NMR (200 MHz, CDCl$_3$): δ_H 2.35 (3H, s, CH$_3$), 3.72–3.85 (1H, m, H3), 3.90–3.98 (2H, m, 2×H2), 4.08–4.21 (1H, m, H3'), 4.85 (1H, ddt, J = 10.2, 3.2, 1 Hz, H7), 5.15 (1H, ddd, J = 7.6, 5.9, 1 Hz, H9), 5.96 (1H, dddd, J = 10.2, 5.9, 1.7, 1 Hz, H8), 6.46 (1H, dd, J = 3.2, 1.7 Hz, H6a), 6.91 (dt, J = 7.6, 1Hz, H10), 6.95–7.0 (2H, m, aromat.), 7.13–7.17 (1H, m, aromat.), 7.24–7.32 (1H, m aromat.). ^{13}C NMR (50 MHz, CDCl$_3$): δ_C 21.2 (CH$_3$), 44.7 (C3), 51.5 (C2), 67.9 (H6a), 100.0 (C9), 112.9 (C7), 124.8 (C8), 125.2 (C10), 126.8, 128.9, 129.1, 130.5, 135.1, 139.2 (6C aromat.),

151.4 (C=N), 152.1 (C=O). Anal. Calcd for $C_{16}H_{16}N_4O$ (280,32): C, 68.55; H, 5.75; N, 19.99%. Found: C,68.67; H, 5.67; N, 19.88%

6-(3,4-dimethylphenyl)-2,3-dihydro-6aH-imidazo[1,2-a]pyrido[1,2-c][1,3,5]triazin-5(6H)-one (3d). Beige crystals from ethanol/water, yield 30%, 2.2 g, mp (dec.): 153–154 °C; IR (ν_{max}, cm^{-1}): 3065, 3028, 2969, 2875, 1696 (C=O), 1661 (C=N), 1651, 1587, 1371, 1331, 772. ^{1}H NMR (200 MHz, CDCl$_3$): δ_H 2.24 (3H, s, CH$_3$), 2.25 (3H, s, CH$_3$), 3.76–3.84 (1H, m, H3), 3.90–3.98 (2H, m, 2×H2), 4.08–4.17 (1H, m, H3'), 4.87 (1H, ddt, J = 10.2, 3, 1 Hz, H7), 5.14 (1H, ddd, J = 7.6, 5.9, 1 Hz, H9), 5.95 (1H, dddd, J = 10.2, 5.9, 1.7, 1 Hz, H8), 6.44 (1H, dd, J = 3, 1.7 Hz, H6a), 6.9 (dd, J = 7.6, 1Hz, H10), 6.90 (1H, d, J = 7.9 Hz, aromat.), 6.96 (1H, s, aromat.), 7.15 (1H, d, J = 7.9 Hz, aromat.); ^{13}C NMR (50 MHz, CDCl$_3$): δ_C 19.4 (CH$_3$), 19.8 (CH$_3$), 44.8 (C3), 51.4 (C2), 67.9 (C6a), 100.1 (C9), 113.1 (C7), 124.8 (C8), 125.0 (C10), 127.0, 130.3, 129.8, 132.8, 136.9, 137.7 (6C, aromat.), 151.5 (C=N), 152.0 (C=O). Anal. Calcd for $C_{17}H_{18}N_4O$ (294,35): C, 69.37; H, 6.16; N, 19.03%. Found: C, 69.28; H, 6.19; N, 19.09%

6-(3,4-dichlorophenyl)-2,3-dihydro-6aH-imidazo[1,2-a]pyrido[1,2-c][1,3,5]triazin-5(6H)-one (3g). Yellow crystals ethanol/methanol/water, yield, 42%, 3.5 g, mp (dec.): 176–177 °C; IR (ν_{max}, cm^{-1}): 3067, 3032, 2970, 2878, 1696 (C=O), 1662 (C=N), 1653, 1588, 1490, 1374, 1333, 771. ^{1}H NMR (200 MHz, CDCl$_3$): δ_H 3.71–3.84 (1H, m, H3), 3.91–4.00 (2H, m, 2×H2), 4.08–4.21 (1H, m, H3'), 4.84 (1H, dd, J = 10.2, 3.3 Hz, H7), 5.15–5.22 (1H, m, H9), 6.02–6.10 (1H, m, H8), 6.49 (1H, dd, J = 3.3, 1.7 Hz, H6a), 6.88 (d, J = 7.6, H10), 7.05 (1H, dd, J = 8.5, 2.4 Hz, aromat.), 7.32 (1H, d, J = 2.4 Hz, aromat.), 7.47 (1H, d, J = 8.5 Hz, aromat.). ^{13}C NMR (50 MHz, CDCl$_3$): δ_C 44.7 (C3), 51.6 (C2), 67.9 (C6a), 99.9 (C9), 112.0 (C7), 125.1 (C8), 126.3 (C10), 129.3, 130.6, 131.9, 132.5, 132.9, 134.4 (6C, aromat.), 151.0 (C=N), 151.4 (C=O). Anal. Calcd for $C_{15}H_{12}Cl_2N_4O$ (335.19): C, 53.75; H, 3.61; N, 16.72%. Found: C, 53.69; H, 3.53; N, 16.79%.

12-phenyl-2,3,6,7,8a,9,14,15-octahydro-9,15-ethenodiimidazo[1',2':1,2;1",2":5,6] [1,3,5]triazino[3,4-d][1,2,4]triazolino[1,2-a][1,2,4]triazine-11(10H),13(12H)-dione (6)
To a cooled (–20 °C) and stirred solution of **2** (0.56 g, 2.6 mmol) in CH$_2$Cl$_2$ (80 ml) a solution of 4-phenyl-1,2,4-triazoline-3,5-dione (0.5 g, 2.86 mmol) in CH$_2$Cl$_2$ (50 ml) was added dropwise over 30 minutes under a nitrogen atmosphere. The stirring was continued for additional 30 min. To the oil, obtained after evaporation of the reaction mixture, acetone (30 ml) was added and on stirring beige solid precipitated. The acetone was decanted and the solid was extracted three times with equal portions of acetone (~20 ml). The combined acetone extracts were evaporated and the resulting solid was stirred for 1 h with water (10 ml), filtered off, dried and purified through flash column chromatography using a mixture of dichloromethane, acetone and methanol (3:2:0.5 v/v/v) as the eluent. Recrystallization from benzene gave colorless crystals of the product, yield 24 %, 180 mg, mp (dec.): 228–230 °C; IR (ν_{max}, cm^{-1}): 3436 (H$_2$O), 3036, 2958, 2883, 1779 (C=O urazole), 1724 (C=O urazole), 1656 (C=N), 1647 (C=N), 1496, 1410, 773, 733. ^{1}H NMR (200 MHz, DMSO-d_6): δ_H 3.03–3.13 (1H, m, H7), 3.29–3.45 (1H, m, H7'), 3.57–3.72 (6H, m, 2×H2, 2×H3, 2×H6), 4.89 (1H, d, J = 2.5 Hz, H8a), 5.45 (1H, dt, J = 5.9, 2

Hz, H9), 6.30 (1H, dd, J = 4.9, 1.5 Hz, H15), 6.56–6.62 (1H, m, H18), 6.99 (1H, ddd, J = 8.3, 4.9, 1.5 Hz, H17), 7.39–7.57 (5H, m, Ph). ^{13}C NMR (50 MHz, DMSO-d_6): δ_C 46.1 (C3), 48.8 (C7), 50.9 (C6), 51.1 (C2), 52.7 (C9), 62.0 (C15), 68.2 (C8a), 126.3 (2C aromat.), 126.8 (C18), 128.9, 129.2, 130.7 (4C aromat.), 131.5 (C17), 149.6 (C17a=N), 153.62 (C4a=N), 154.2, 155.5 (2×C=O, urazole). Anal. Calcd for $C_{19}H_{18}N_8O_2 \cdot C_6H_6 \cdot H_2O$ (486.53): C, 61.72; H, 5.39; N, 23.03%. Found: C, 61.65; H, 5.20; N, 22.89%

General procedure of the preparation of 6-aryl-2,3,6a,7,12,13-hexahydro-7,13-ethenoimidazo[1',2':1,2][1,3,5]triazino[3,4-*d*][1,2,4]triazolino[1,2-*a*][1,2,4]triazine-6(5*H*),9(8*H*),11(10*H*)-triones (7a–h)

To a cooled (–20 °C) and stirred solution of the appropriate 6-aryl-2,3-dihydro-6a*H*-imidazo[1,2-*a*]pyrido[1,2-*c*][1,3,5]triazin-5(6*H*)-one (2.6 mmol) in CH_2Cl_2 (80 ml) a solution of 4-phenyl-1,2,4-triazoline-3,5-dione (0.5 g, 2.86 mmol) in CH_2Cl_2 (50 ml) was added dropwise over 30 minutes under a nitrogen atmosphere. The stirring was continued for additional 30 min. To the oil, obtained after evaporation of the reaction mixture, ethyl acetate (10 ml) followed by hexane (30 ml) were added. The precipitated solid was filtered off and purified through flash column or preparative thin layer chromatography.

6,10-diphenyl-2,3,6a,7,12,13-hexahydro-7,13-ethenoimidazo[1',2':1,2][1,3,5]triazino[3,4-*d*][1,2,4]triazolino[1,2-*a*][1,2,4]triazine-6(5*H*),9(8*H*),11(10*H*)-trione (7a). Two chromatographic purifications were needed, the first one with ethyl acetate/hexane 3:1→4:1 v/v yielded 360 mg of roughly purified product, second one was performed with diethyl ether/dichloromethane/ethyl acetate 4:1:1 v/v/v. White solid, yield 23%, 280 mg, mp (dec.): 198–199 °C; IR (ν_{max}, cm^{-1}) 3094, 3061, 2960, 2895, 1777 (C=O urazole), 1712 (C=O urazole), 1688 (C5=O), 1665 (C=N), 1397. ^{1}H NMR (200 MHz, DMSO-d_6): δ_H 3.62–3.90 (4H, m, -CH$_2$–CH$_2$- imidaz.), 4.53–4.57 (1H, m, H7), 5.96 (1H, d, J = 2.5 Hz, H6a), 6.40 (1H, dd, J = 5.2, 1.5 Hz, H13), 6.43–6.50 (1H, m, H16), 7.16 (1H, ddd, J = 7.8, 5.2, 1.5 Hz, H15), 7.34–7.57 (10H, m, 2×Ph). ^{13}C NMR (50 MHz, DMSO-d_6): δ_C 44.7 (C3), 50.8 (C2), 52.3 (C7), 62.0 (C13), 67.2 (C6a), 125.3 (C16), 126.2, 128.5, 128.9, 129.1, 129.7 (C aromat), 133.1 (C15), 137.4 (C aromat), 149.0 (C=N), 151.2 (C5=O), 154.0, 155.5 (2×C=O urazole); Anal. Calcd for $C_{23}H_{19}N_7O_3$ (441.44): C, 62.58; H, 4.34; N, 22.21%. Found: C, 62.42, H, 4.32; N, 22.18%

6-(4-methylphenyl)-10-phenyl-2,3,6a,7,12,13-hexahydro-7,13-ethenoimidazo[1',2':1,2][1,3,5]triazino[3,4-*d*][1,2,4]triazolino[1,2-*a*][1,2,4]triazine-6(5*H*),9(8*H*),11(10*H*)-trione (7b). Eluent: ethyl acetate/hexane 3:2→4:1 v/v. White solid, yield 24%, 290 mg, mp (dec.): 199–200 °C, IR (ν_{max}, cm^{-1}): 3072, 2987, 2881, 1781 (C=O urazole), 1721 (C=O urazole), 1702 (C5=O), 1659 (C=N), 1398, 775, 727. ^{1}H NMR (500 MHz, DMSO-d_6): δ_H 2.37 (3H, s, CH$_3$), 3.62–3.67 (1H, m, H3), 3.77 (2H, t, J = 8.3 Hz, 2×H2), 3.84–3.79 (1H, m, H3'), 4.55 (1H, dd, J = 3.4, 2.0 Hz, H7), 5.92 (1H, d, J = 2.4 Hz, H6a), 6.37 (1H, d, J = 4.9 Hz, H13), 6.47 (1H, t, J = 6.8 Hz, H16), 7.14–7.16 (1H, m, H15), 7.22–7.23 (2H, m, Ph), 7.32 (2H, d, J = 7.6 Hz, C$_6$H$_4$), 7.39 (2H, d, J = 7.6 Hz, C$_6$H$_4$), 7.43–7.46 (1H, m, Ph), 7.49–7.52 (2H, m, Ph).

^{13}C NMR (50 MHz, DMSO-d_6): δ_C 20.7 (CH$_3$), 44.7 (C3), 50.8 (C2), 52.3 (C7), 62.0 (C13), 67.2 (C6a), 125.4 (C16), 126.2, 128.4, 128.9, 129.2, 130.2, 130.6 (10 C aromat), 133.0 (C15), 134.8, 138.1 (2C aromat), 149.1 (C=N), 151.3 (C5=O), 154.1, 155.3 (2×C=O urazole). Anal. Calcd for C$_{24}$H$_{21}$N$_7$O$_3$ (455.47): C, 63.29; H, 4.65; N, 21.53%; Found: C, 63.23; H, 4.59; N, 21.48%.

6-(3-methylphenyl)-10-phenyl-2,3,6a,7,12,13-hexahydro-7,13-ethenoimidazo[1',2':1,2] [1,3,5]triazino[3,4-d][1,2,4]triazolino[1,2-a][1,2,4]triazine-6(5H),9(8H),11(10H)-trione (7c).
Eluents: ethyl acetate/hexane 6:1 v/v until the first stereoisomer was collected followed by ethyl acetate/methanol 9:0.5 v/v which enabled elution of the second stereoisomer. The evaporated solids were washed with acetone/diethyl ether 1:1 v/v (10 ml), filtered off and dried.

Stereoisomer 1: white solid, yield 42%, 490 mg, mp (dec.): 218–220 °C; IR (ν_{max}, cm^{-1}) 3058, 2987, 2950, 2877, 1787 (C=O urazole), 1727 (C=O urazole), 1689 (C5=O), 1654 (C=N), 1401, 721. ^{1}H NMR (200 MHz, DMSO-d_6): δ_H 2.36 (3H, s, CH$_3$), 3.61–3.89 (4H, m, -CH$_2$–CH$_2$-imidaz.), 4.53–4.58 (1H, m, H7), 5.92 (1H, d, J = 2.2 Hz, H6a), 6.39 (1H, dd, J = 5.1, 1.5 Hz, H13), 6.45–5.52 (1H, m, H16), 7.12–7.19 (3H, m, H15+2H aromat.), 7.27 (1H, d, J = 7.6 Hz, H aromat. C$_6$H$_4$Me), 7.37–7.54 (6H, m, aromat.). ^{13}C NMR (50 MHz, DMSO-d_6): δ_C 20.8 (CH$_3$), 44.7 (C3), 50.8 (C2), 52.3 (C7), 62.0 (C13), 67.2 (C6a), 125.4 (C16), 126.2, 128.9, 129.0, 129.2, 129 .3, 129.5, 130.6 (10 C aromat), 133.0 (C15), 137.3, 139.4 (2C aromat.), 149.0 (C=N), 151.3 (C5=O), 154.1, 155.3 (2×C=O urazole). Anal. Calcd for C$_{24}$H$_{21}$N$_7$O$_3$ (455,47) C, 63.29; H, 4.65; N, 21.53; Found: C, 63.32; H, 4.61; N, 21.56%.

Stereoisomer 2: white solid, yield 8%, 90 mg, mp (dec.): 190–192 ºC; IR (ν_{max}, cm^{-1}) 3075, 3001, 2923, 2874, 1778 (C=O urazole), 1729 (C=O urazole), 1712 (C5=O), 1689 (C=N), 1400, 774. ^{1}H NMR (200 MHz, DMSO-d_6): δ_H 2.33 (3H, s, CH$_3$), 3.65–3.88 (4H, m, -CH$_2$–CH$_2$-imidaz.) 4.58 (1H, d, J = 5.9 Hz, H7), 5.32 (1H, s, H6a), 6.50 (1H, dd, J = 4.5, ~1 Hz, H13), 6.56–6.67 (1H, m, H16), 6.91–7.01 (1H, m, H15), 7.19–7.51 (9H, m, Ph + H aromat. C$_6$H$_4$Me); ^{13}C NMR (50 MHz, DMSO-d_6): δ_C 20.85 (CH$_3$), 45.2 (C3), 50.7 (C2), 52.8 (C7), 62.4 (C13), 67.0 (C6a), 126.2, 127.4 (C aromat.), 128.7 (C16), 129.1 (C aromat.), 129.7 (C15), 130.7, 137.1, 138.9 (C aromat.), 149.2 (C=N), 152.1 (C5=O), 154.2, 156.1 (2×C=O, urazole). Anal. Calcd for C$_{24}$H$_{21}$N$_7$O$_3$ (455,47) C, 63.29; H, 4.65; N, 21.53; Found: C, 63.20; H, 4.66; N, 21.52%.

6-(3,4-dimethylphenyl)-10-phenyl-2,3,6a,7,12,13-hexahydro-7,13-ethenoimidazo[1',2':1,2] [1,3,5]triazino[3,4-d][1,2,4]triazolino[1,2-a][1,2,4]triazine-6(5H),9(8H),11(10H)-trione (7d).
Eluents: ethyl acetate/hexane 5:1(v/v)→ethyl acetate, two fractions were collected. The evaporated solids are washed with acetone/diethyl ether 1:1 v/v (10 ml), filtered off and dried.

Stereoisomer 1: white solid, yield 58%, 700 mg, mp (dec.): 225–226 °C; IR (ν_{max}, cm^{-1}): 3057, 2927, 2879, 1788 (C=O urazole), 1728 (C=O urazole), 1687 (C5=O), 1655 (C=N), 1401. ^{1}H NMR (500 MHz, DMSO-d_6): δ_H 2.27 (3H, s, CH$_3$), 2.28 (3H, s, CH$_3$), 3.62–3.67 (1H, m, H3), 3.75–3.79 (2H, m, 2×H2), 3.83–3.89 (1H, m, H3'), 4.55–4.56 (1H, m, H7), 5.89 (1H, d, J = 2.4 Hz, H6a), 6.38 (1H, dd, J = 4.9, ~1 Hz, H13), 6.47–6.50 (1H, m, H16), 7.02–7.12 (2H, m, H aromat. C$_6$H$_3$Me$_2$), 7.14–7.17 (1H, m, H15), 7.27 (1H, d, J = 8.3 Hz, H aromat. C$_6$H$_3$Me$_2$), 7.37 (1H, d, J = 7.3 Hz, Ph), 7.40 (1H, s, H aromat. C$_6$H$_3$Me$_2$), 7.45 (1H, t, J = 7.3 Hz, Ph), 7.51 (1H, t, J = 7.3 Hz, Ph). ^{13}C NMR spectrum could not be measured because of the poor solubility of

the compound in DMSO. Anal. Calcd for $C_{25}H_{23}N_7O_3$ (469.50): C, 63.96; H, 4.94; N, 20.88%. Found: C, 63.88; H, 4.90; N, 20.93%.

Stereoisomer 2: white solid, yield 8%, 90 mg; mp (dec.): 211–212 °C; IR (v_{max}, cm^{-1}): 3072, 2993, 2874, 1777 (C=O urazole), 1712 (C=O), 1655 (C=N), 1397. ^{1}H NMR (500 MHz, DMSO-d_6): δ_H 2.23 (3H, s, CH$_3$), 2.26 (3H, s, CH$_3$), 3.67–3.72 (1H, m, H3), 3.74–3.84 (2H, m, 2×H2), 3.88–3.93 (1H, m, H3'), 4.58 (1H, d, J = 6.3 Hz, H7), 5.28 (1H, d, J = 1.5 Hz, H6a), 6.48 (1H, dd, J = 5.4, 1.5 Hz, H13), 6.61 (1H, dt, J = 7.1, 1.5 Hz, H16), 6.95 (1H, dt, J = 6.6, 1.5 Hz, H15), 7.12 (1H, d, J = 8.1 Hz, H aromat. $C_6H_3Me_2$), 7.21 (1H, s, H aromat. $C_6H_3Me_2$), 7.23 (1H, d, J = 8.1 Hz, H aromat. $C_6H_3Me_2$), 7.37 (2H, d, J = 7.3 Hz, Ph), 7.43 (1H, t, J = 7.3 Hz, Ph), 7.49 (1H, t, J = 7.3 Hz, Ph). ^{13}C NMR (50 MHz, DMSO-d_6): δ_H 19.0 (CH$_3$), 19.4 (CH$_3$), 45.2 (C3), 50.6 (C2), 52.9 (C7), 62.4 (C13), 67.1 (C6a), 126.2, 126.5, 127.4 (4C aromat.), 128.7 (C16), 129.1 (2C aromat.), 129.7 (C15), 129.9, 130.2, 130.7, 134.7, 136.6, 137.4 (6C aromat.), 149.2 (C=N), 152.2 (C5=O), 154.2, 156.1 (2×C=O, urazole). Anal. Calcd for $C_{25}H_{23}N_7O_3$ (469.50): C, 63.96; H, 4.94; N, 20.88%. Found: C, 63.98; H, 4.97; N, 20.84%.

6-(4-chlorophenyl)-10-phenyl-2,3,6a,7,12,13-hexahydro-7,13-ethenoimidazo[1',2':1,2] [1,3,5]triazino[3,4-d][1,2,4]triazolino[1,2-a][1,2,4]triazine-6(5H),9(8H),11(10H)-trione (7e).
Eluents: ethyl acetate/hexane 8:3 v/v until the first stereoisomer was collected followed by ethyl acetate/methanol 9:0.5 v/v which enabled elution of the second stereoisomer.

Stereoisomer 1: white solid, yield 32%, 390 mg, mp (dec.) 194–196 °C; IR (v_{max}, cm^{-1}): 3055, 2979, 2911, 1779 (C=O urazole), 1717 (C=O urazole), 1700 (C=O), 1690 (C=O), 1667 (C=N). ^{1}H NMR (500 MHz, DMSO-d_6): δ_H 3.62–3.67 (1H, m, H3), 3.76–3.79 (2H, m, 2×H2), 3.85–3.90 (1H, m, H3'), 4.66–4.67 (1H, m, H7), 5.97 (1H, d, J = 2.4 Hz, H6a), 6.4 (1H, d, J = 5.0 Hz, H13), 6.47 (1H, t, J = 6.8 Hz, H16), 7.15 (1H, ddd, J = 6.8, 5, 1.5 Hz, H15), 7.38–7.41 (4H, m, aromat.), 7.45 (1H, t, J = 7.3 Hz, Ph), 7.5 (2H, t, J = 7.3 Hz, Ph), 7.60 (1H, d, J = 8.8 Hz, C_6H_4Cl); ^{13}C NMR (125 MHz, DMSO-d_6): δ_C 44.9 (C3), 51.0 (C2), 52.4 (C7), 62.2 (C13), 67.2 (C6a), 125.5 (C16), 126.4, 129.1, 129.4, 130.0, 130.7 (11C, aromat), 133.3 (C15), 136.5 (1C aromat), 149.1 (C=N), 151.3 (C5=O), 154.3, 155.4 (2×C=O, urazole); MS, *m/z* (%) = 248 ($C_{11}H_9ClN_4O$, 56), 250 ($C_{11}H_9ClN_4O+2$, 18), 227 ($C_{12}H_9N_3O_2$, 100), 138 (75), 119 (65). Anal. Calcd for $C_{23}H_{18}ClN_7O_3$ (475.89) C, 58.05; H, 3.81; N, 20.60; Found: C, 58.12; H, 3.76; N, 20.59%.

Stereoisomer 2: white solid, yield 8%, 96 mg, mp (dec.) 211–213 °C; IR (v_{max}, cm^{-1}): 3037, 2993, 2874, 1775 (C=O urazole), 1736 (C=O urazole), 1711 (C5=O), 1659 (C=N), 1395. ^{1}H NMR (500 MHz, DMSO-d_6): δ_H 3.68–3.73 (1H, m, H3), 3.75–3.85 (2H, m, 2×H2), 3.90–3.97 (1H, m, H3'), 4.65 (1H, d, J = 5.9 Hz, H7), 5.38 (1H, s, H6a), 6.49 (1H, d, J = 5.4 Hz, H13), 6.59–6.62 (1H, m, H16), 6.95–6.98 (1H, m, H15), 7.35 (2H, d, J = 7.8 Hz, C_6H_4Cl), 7.42–7.51 (5H, m, Ph), 7.55 (2H, d, J = 7.8 Hz, C_6H_4Cl). ^{13}C NMR (125 MHz, DMSO-d_6) δ 45.2 (C3), 50.7 (C2), 52.6 (C7), 62.5 (C13), 66.9 (C6a), 126.3, 127.4 (3C aromat.), 128.8 (C16), 129.2, 129.4 (4C aromat.), 129.9 (C15), 130.7, 131.3, 133.0, 136.2 (5C aromat.), 149.1 (C=N), 152.0 (C5=O), 154.2, 156.1 (2×C=O, urazole). MS, *m/z* (%) = 248 ($C_{11}H_9ClN_4O$, 73), 250

($C_{11}H_9ClN_4O+2$, 24), 227 ($C_{12}H_9N_3O_2$, 77), 138 (100), 119 (63). Anal. Calcd for $C_{23}H_{18}ClN_7O_3$ (475.89) C, 58.05; H, 3.81; N, 20.60; Found: C, 57.89; H, 3.78; N, 20.62%.

6-(3-chlorophenyl)-10-phenyl-2,3,6a,7,12,13-hexahydro-7,13-ethenoimidazo[1',2':1,2] [1,3,5]triazino[3,4-*d*][1,2,4]triazolino[1,2-*a*][1,2,4]triazine-6(5*H*),9(8*H*),11(10*H*)-trione (7f).
Eluent: ethyl acetate/hexane 3:1 v/v. White solid, yield 24%, 330 mg, mp (dec.) 191–193 °C; IR (ν_{max}, cm^{-1}): 3088, 3037, 2920, 2871, 1776 (C=O urazole), 1721 (C=O urazole), 1693 (C5=O), 1662 (C=N), 1453, 1398, 773, 745. ^{1}H NMR (500 MHz, DMSO-d_6): δ_H 3.62–3.68 (1H, m, H3), 3.78 (2H, t, J = 8.3 Hz, 2×H2), 3.85–3.90 (1H, m, H3'), 4.68 (1H, dt, J = 5.4, 1.5 Hz, H7), 5.98 (1H, d, J = 2.4 Hz, H6a), 6.40 (1H, dd, J = 4.9, 1.5 Hz H13), 6.47–6.49 (1H, m, H16), 7.15 (1H, ddd, J = 7.8, 4.9, 1.5 Hz, H15), 7.31–7.36 (1H, m, C_6H_4Cl), 7.4 (1H, d, J = 8.3 Hz, C_6H_4Cl), 7.41 (1H, s, C_6H_4Cl), 7.44–7.47 (1H, m, Ph), 7.50–7.56 (4H, m, Ph). ^{13}C NMR (50 MHz, DMSO-d_6): δ_C 44.7 (C3), 50.8 (C2), 52.2 (C7), 62.0 (C13), 67.0 (C6a), 125.3 (C16), 126.2, 127.5, 128.6, 128.8, 128.9, 129.2, 130.6, 131.2 (10 C aromat.), 133.1 (C15), 133.7, 138.8 (2C aromat.), 148.8 (C=N), 151.1 (C5=O), 154.1, 155.3 (2×C=O, urazole). Anal. Calcd for $C_{23}H_{18}ClN_7O_3$ (475.89): C, 58.05; H, 3.81; N, 20.60%. Found: C, 58.01; H, 3.77; N, 20.64%.

6-(3,4-dichlorophenyl)-10-phenyl-2,3,6a,7,12,13-hexahydro-7,13-ethenoimidazo[1',2':1,2] [1,3,5]triazino[3,4-*d*][1,2,4]triazolino[1,2-*a*][1,2,4]triazine-6(5*H*),9(8*H*),11(10*H*)-trione (7g).
Eluents: ethyl acetate/hexane 3:2→4:1 v/v. Two fractions were collected. The evaporated solids were washed with ethyl acetate, filtered off and dried.

Stereoisomer 1: white solid, yield 34%, 440 mg, mp (dec.): 214–215 ºC; IR (ν_{max}, cm^{-1}): 3058, 3026, 2928, 2878, 1786 (C=O urazole), 1728 (C=O urazole), 1691 (C5=O), 1656 (C=N), 1401. ^{1}H NMR (500 MHz, DMSO-d_6): δ_H 3.62–3.67 (1H, m, H3), 3.73–3.82 (1H, m, 2×H2), 3.85–3.90 (1H, m, H3'), 4.84–4.86 (1H, m, H7), 5.97 (1H, d, J = 2 Hz, H6a), 6.39 (1H, d, J = 4.9 Hz, H13), 6.46–6.48 (1H, m, H16), 7.12–7.15 (1H, m, H15), 7.36 (1H, dd, J = 8.3, ~1 Hz, $C_6H_3Cl_2$), 7.40 (2H, d, J = 7.8 Hz, Ph), 7.45 (1H, t, J = 7.8 Hz, Ph), 7.52 (2H, t, J = 7.8 Hz, Ph), 7.74 (1H, d, J~1Hz, $C_6H_3Cl_2$), 7.80 (1H, d, J = 8.3 Hz, $C_6H_3Cl_2$). ^{13}C NMR (50 MHz, DMSO-d_6): δ_C 44.6 (C3), 50.8 (C2), 52.0 (C7), 62.0 (C13), 66.9 (C6a), 125.4 (C16), 126.2, 128.9, 129.0, 129.2, 130.6, 130.7, 131.4, 131.5, 131.9 (11C, aromat.), 133.1 (C15), 137.3 (1C aromat.), 148.7 (C=N), 151.0 (C5=O), 154.1, 155.2 (2×C=O, urazole). Anal. Calcd for $C_{23}H_{17}Cl_2N_7O_3$ (510.33): C, 54.13; H, 3.36; N, 19.21%. Found: C, 54.06; H, 3.29; N, 19.05%.

Strereoisomer 2: white solid, yield 6%, 80 mg, mp (dec.): 200–201; IR (ν_{max}, cm^{-1}): 3071, 2988, 2876, 1782 (C=O urazole), 1721 (C=O urazole), 1704 (C5=O), 1664 (C=N), 1399. ^{1}H NMR (500 MHz, DMSO-d_6): δ_H 3.67–3.73 (1H, m, H3), 3.75–3.85 (2H, m, 2×H2), 3.90–3.95 (1H, m, H3'), 4.75 (1H, d, J = 6.3 Hz, H7), 5.37 (1H, s, H6a), 6.50 (1H, d, J = 4.9 Hz, H13), 6.58–6.60 (1H, m, H16), 6.97 (1H, t, J = 6.3 Hz, H15), 7.35–7.37 (2H, m, J = 7.8 Hz, H aromat.), 7.42–7.45 (2H, m, H aromat.), 7.48–7.51 (2H, m, H aromat.), 7.76 (1H, d, J = 8.3 Hz, $C_6H_3Cl_2$), 7.82 (1H, d, J~1 Hz, $C_6H_3Cl_2$); ^{13}C NMR (50 MHz, DMSO-d_6): δ_C 45.1 (C3), 50.7 (C2), 52.5 (C7), 62.4 (C13), 67.1 (C6a), 126.2, 127.3 (3C aromat.), 128.7 (C16), 128.9, 129.1 (3C aromat.), 129.9 (C15), 130.2, 130.7, 131.0, 131.3, 131.6, 137.2 (6C aromat.), 148.9 (C=N), 151.9 (C5=O), 154.1,

156.0 (2×C=O, urazole). Anal. Calcd for $C_{23}H_{17}Cl_2N_7O_3$ (510.33): C, 54.13; H, 3.36; N, 19.21%. Found: C, 54.02; H, 3.32; N, 19.23%.

6-(4-methoxyphenyl)-10-phenyl-2,3,6a,7,12,13-hexahydro-7,13-ethenoimidazo[1',2':1,2] [1,3,5]triazino[3,4-*d*][1,2,4]triazolino[1,2-*a*][1,2,4]triazine-6(5*H*),9(8*H*),11(10*H*)-trione (7h). Eluents: ethyl acetate/hexane 4:1 v/v →ethyl acetate. The evaporated solid was washed with acetone/diethyl ether 1:1 v/v (10 ml), filtered off and dried. White solid, yield 46%, 560 mg, mp (dec.): 202–203 ºC; IR (ν_{max}, cm^{-1}): 3119, 2936, 2889, 1781 (C=O urazole), 1720 (C=O urazole), 1697 (C5=O), 1659 (C=N), 1401, 1243. ^{1}H NMR (500 MHz, DMSO-d_6): δ_H 3.61–3.67 (1H, m, H3), 3.57–3.78 (2H, m, 2×H2), 3.81 (3H, s, CH$_3$), 3.81–3.89 (1H, m, H3'), 4.56–4.57 (1H, m, H7), 5.88 (1H, d, J = 2 Hz, H6a), 6.39 (1H, dd, J = 4.9, ~1 Hz, H13), 6.48 (1H, t, J = 6.8 Hz, H16), 7.06 (2H, d, J = 8.8 Hz, H aromat. C_6H_4OMe), 7.14–7.17 (1H, m, H15), 7.24–7.30 (2H, m, H aromat. C_6H_4OMe), 7.40 (2H, d, J = 7.3 Hz, Ph), 7.45 (1H, t, J = 7.3 Hz, Ph), 7.51 (2H, t, J = 7.3 Hz, Ph). ^{13}C NMR (50 MHz, DMSO-d_6): δ_C 44.7 (C3), 50.8 (C2), 52.4 (C7), 55.4 (CH$_3$), 62.0 (C13), 67.4 (C6a), 114.9 (2C aromat.), 125.4 (C16), 126.2, 128.9, 129.2, 129.7, 129.8, 130.6 (9C aromat.), 133.0 (C15), 149.1 (C=N), 151.5 (C5=O), 154.1, 155.3 (2×C=O, urazole), 159.0 (1C aromat.). Anal. Calcd for $C_{24}H_{21}N_7O_4$ (471.47): C, 61.14; H, 4.49; N, 20.80%. Found: C, 61.18; H, 4.32; N, 20.69%.

General procedure of preparing the reduced cycloadducts (8, 9a) and (9b)
The procedure is based on the one reported in ref. 22. To the cycloadduct **6**, **7b** or **7e** (0.3 mmol) dissolved in CH$_2$Cl$_2$ (~1.5 ml) *o*-nitrobenzenesulfonylhydrazide^{28} (0.33 g, 1.5 mmol) was added followed by triethylamine (0.24 g, 0.33 ml, 2.4 mmol). The resulting slurry was stirred for 20 hours at room temperature. The homogenous reaction mixture was then diluted with CH$_2$Cl$_2$ (10 ml) and washed successively with saturated sodium bicarbonate solution (7 ml) and water (7 ml). The organic phase was dried over MgSO$_4$, concentrated under reduced pressure and purified by flash chromatography.

12-phenyl-2,3,6,7,8a,9,14,15-octahydro-9,15-ethanodiimidazo[1',2':1,2;1",2":5,6] [1,3,5]triazino[3,4-*d*][1,2,4]triazolino[1,2-*a*][1,2,4]triazine-11(10*H*),13(12*H*)-dion (8). Eluent: dichloromethane/acetone/methanol 3:2:0.8. White solid, yield 50%, 45 mg, mp (dec.): 230–232 ºC; IR (ν_{max}, cm^{-1}): 2994, 2945, 2880, 1776 (C=O urazole), 1716 (C=O urazole), 1670 (C5=O), 1646 (C=N), 1410, 773, 692. ^{1}H NMR (200 MHz, DMSO-d_6): δ_H 2.05–2.28 (m, 4H, 2×H17+2×H18), 2.77–2.95 (m, 1H, H7), 3.25–3.80 (m, 7H, 2×H2, 2×H3, 2×H6, H7'), 4.62–4.46 (m, 1H, H8a/H9), 4.74 (br. s, 1H, H8a/H9), 5.86 (br. s, 1H, H15), 7.38–7.60 (m, 5H, Ph). ^{13}C NMR (50 MHz, DMSO-d_6): δ_c 16.5 (C17/C18), 24.5 (C17/C18), 45.9 (C3), 48.6 (C7), 50.5 (C6), 51.0 (C2), 51.2 (C9), 61.3 (C15), 68.7 (C8a), 126.6, 128.6, 129.0, 131.1 (6C, Ph), 148.5 (C16a=N), 153.5 (C4a=N), 154.3, 156.2 (2×C=O urazole). Anal. Calcd for $C_{19}H_{20}N_8O_2$ (392.41): C, 58.15; H, 5.14; N, 28.55%. Found: C, 58.01; H, 5.22; N, 28.87%.

6-(4-methylphenyl)-10-phenyl-2,3,6a,7,12,13-hexahydro-7,13-ethanoimidazo[1',2':1,2] [1,3,5]triazino[3,4-*d*][1,2,4]triazolino[1,2-*a*][1,2,4]triazine-6(5*H*),9(8*H*),11(10*H*)-trione (9a). Eluent: ethyl acetate/hexane 4:1 v/v. White solid, yield 93%, 130 mg, mp (dec.) 201–203 ºC; IR

(ν_{max}, cm^{-1}): 3034, 2920, 2862, 1718 (C=O urazole), 1723 (C=O urazole), 1702 (C5=O), 1664 (C=N), 1408, 767. ^{1}H NMR (200 MHz, DMSO-d_6): δ_H 1.95–2.34 (4H, m, 2×H12+2×H13), 2.34 (3H, s, CH$_3$), 3.60–3.93 (5H, m, -CH$_2$–CH$_2$- imidaz.+H7), 5.82 (1H, s, H13), 5.96 (1H, s, H6a), 7.22–7.27 (4H, m, aromat.), 7.43–7.52 (5H, m, aromat.). ^{13}C NMR (50 MHz, DMSO-d_6): δ_c 16.0 (C15/16), 20.6 (CH$_3$), 24.4 (C15/16), 44.7 (C3), 50.1 (C2), 50.7 (C7), 61.1 (C13), 67.6 (C6a), 126.6, 127.8, 128.6, 128.9, 130.0, 131.0, 134.8, 137.6 (12C, Ph+C$_6$H$_4$), 148.1 (C14a=N), 152.0 (C5=O), 153.4, 153.8 (2×C=O urazole). Anal. Calcd for C$_{24}$H$_{23}$N$_7$O$_3$ (457.48): C, 63.01; H, 5.07; N, 21.43%. Found: C, 63.11; H, 4.88; N, 21.41%.

**6-(4-chlorophenyl)-10-phenyl-2,3,6a,7,12,13-hexahydro-7,13-ethanoimidazo[1',2':1,2]
[1,3,5]triazino[3,4-*d*][1,2,4]triazolino[1,2-*a*][1,2,4]triazine-6(5*H*),9(8*H*),11(10*H*)-trione (9b).**
Eluents: ethyl acetate/hexane 6:1→ethyl acetate.

Stereoisomer 1: Eluents: ethyl acetate/hexane 6:1→ethyl acetate. White solid, yield 55%, 145 mg, mp (dec.): 235–337 ℃ (acetonitrile); IR (ν_{max}, cm^{-1}): 3072, 2951, 2878, 1778 (C=O urazole), 1718 (C=O, urazole), 1649 (C5=O), 1656 (C=N), 1492, 1416, 1397, 763. ^{1}H NMR (500 MHz, DMSO-d_6): δ_H 1.94–1.99 (1H, m), 2.07–2.12 (1H, m), 2.18–2.23 (1H, m), 2.32–2.37 (1H, m) (2×H15+2×H16), 3.61–3.66 (1H, m, H3), 3.69–3.78 (2H, m, 2×H2), 3.85–3.90 (1H, m, H3'), 4.01 (1H, s, H7), 5.87 (1H, s, H13), 5.96 (1H, s, H6a), 7.42 (2H, d, J = 8.8 Hz, C$_6$H$_4$Cl), 7.45–7.48 (1H, m, Ph), 7.51–7.56 (4H, m, Ph), 7.58 (2H, d, J = 8.8 Hz, C$_6$H$_4$Cl). ^{13}C NMR (50 MHz, DMSO-d_6): δ_c 16.0 (C15/16), 24.4 (C15/16), 44.7 (C3), 50.0 (C2), 50.7 (C7), 61.2 (C13), 67.3 (C6a), 126.5, 128.6, 129.0, 129.5, 129.9, 131.0, 132.6, 136.4 (12C, Ph+C$_6$H$_4$Cl), 147.9 (C14a=N), 151.7 (C5=O), 153.5, 153.9 (2×C=O urazole). Anal. Calcd for C$_{23}$H$_{20}$ClN$_7$O$_3$ (477.90): C, 57.80; H, 4.22; N, 20.52%. Found: C, 57.63; H, 4.20; N, 20.74%.

Stereoisomer 2: Eluents: ethyl acetate/hexane 6:1→ethyl acetate. Yellow solid, yield 45%, 65 mg, mp (dec.): 214–215 ℃; IR (ν_{max}, cm^{-1}): 3061, 2953, 2879, 1781 (C=O urazole), 1713 (C=O urazole+C5=O), 1664 (C=N), 1493, 1406, 768. ^{1}H NMR (500 MHz, DMSO-d_6): δ_H 1.99–2.26 (4H, m, 2×H15+2×H16), 3.65–3.75 (3H, m, -CH$_2$–CH$_2$- imidaz.), 3.86–3.91 (1H, m, -CH$_2$–CH$_2$- imidaz.), 4.19 (1H, br. s, H7), 5.74 (1H, s, H6a), 6.11 (1H, br. s, H13), 7.39 (2H, d, J = 8.3 Hz, C$_6$H$_4$Cl), 7.42–7.54 (9H, m, Ph+C$_6$H$_4$Cl). ^{13}C NMR (50 MHz, DMSO-d_6): δ_c 21.2 (C15/16), 25.2 (C15/16), 44.9 (C3), 49.4 (C2), 50.5 (C7), 62.3 (C13), 70.0 (C6a), 126.3, 128.3, 129.0, 130.7, 131.3, 132.4, 136.3 (12C, Ph+C$_6$H$_4$Cl), 149.1 (C14a=N), 151.7, 152.0 (3C, C5=O, 2×C=O urazole). Anal. Calcd for C$_{23}$H$_{20}$ClN$_7$O$_3$ (477.90): C, 57.80; H, 4.22; N, 20.52%. Found: C, 57.63; H, 4.16; N, 20.44%.


Figure 5. Numbering of atoms used to describe ^{1}H and ^{13}C NMR spectra of compounds **11a–b**.

General procedure of preparing compounds (11a–b)

To a cooled (–20 °C) and stirred solution of the appropriate 6-aryl-2,3-dihydro-6a*H*-imidazo[1,2-*a*]pyrido[1,2-*c*][1,3,5]triazin-5(6*H*)-one (1.8 mmol) in CH_2Cl_2 (30 ml) a cold solution of phthalazine-1,4-dione **5** in acetonitrile (prepared from phthalhydrazide (2.9 g, 18 mmol) and lead tetraacetate (7.94 g, 18 mmol) according to Clement[24]) was added dropwise until no further consumption of the dienophile was observed. The reaction mixture was filtered under reduced pressure and the solution evaporated to give a solid residue that was subjected to preparative thin layer chromatography.

6-(4-methylphenyl)-2,3,6a,7,16,17-hexahydro-7,16-ethenoimidazo[1',2':1,2]
[1,3,5]triazino[3,4-*d*]phthalazino[2,3-*a*][1,2,4]triazine-5(6*H*),9(8*H*),14(15*H*)-trione (11a).
The first chromatographic separation was performed with ethyl acetate/methanol 9:1. The last fraction collected was purified in the next chromatographic separation using dichloromethane/methanol 5:2 v/v as the eluent to afford the desired cycloadduct.

Yellow solid, yield 15%, 120 mg, mp 220–222 °C; IR (v_{max}, cm^{-1}): 3050, 2923, 2872, 1698 (C=O), 1681 (C=O), 1654 (C=N), 1396, 1380, 755, 699. ^1H NMR (500 MHz, DMSO-d_6): δ_H 2.40 (3H, s, CH_3), 3.60–3.64 (1H, m, H3), 3.74–3.81 (2H, m, 2×H2), 3.82–3.88 (1H, m, H3'), 5.53–5.55 (1H, m, H7), 5.91 (1H, d, *J* = 2 Hz, H6a), 6.63 (1H, t, *J* = 6.8 Hz, H19), 7.22–7.24 (3H, m, H16+2H aromat.), 7.30 (1H, t, *J* = 6.8 Hz, H18), 7.35 (2H, d, *J* = 8.3 Hz, aromat.), 7.93–7.95 (2H, m, aromat.), 8.12–8.14 (1H, m, aromat.), 8.20–8.22 (1H, m, aromat). ^{13}C NMR (50 MHz, DMSO-d_6): δ_C 20.7 (CH_3), 44.7 (C3), 48.7 (C2), 50.8 (C7), 58.4 (C16), 68.0 (C6a), 127.2, 127.3, 128.0, 128.1, 130.2, 134.0, 134.1, 134.9, 138.0 (14C, aromat.+C18+C19), 149.0 (C=N), 151.2 (C5=O), 152.9, 153.6 (2×C=O of 2,3-dihydrophthalazine-1,4-dione). MS, *m/z* (%) = 228 ($C_{12}H_{12}N_4O$, 88), 212 ($C_{12}H_8N_2O_2$, 70), 118 (100), 104 (56). Anal. Calcd for $C_{24}H_{20}N_6O_3$ (440.45): C, 65.45; H, 4.58; N, 19.08%. Found: C, 65.37; H, 4.53; N, 19.00%.

6-(3,4-dichlorophenyl)-2,3,6a,7,16,17-hexahydro-7,16-ethenoimidazo[1',2':1,2]
[1,3,5]triazino[3,4-*d*]phthalazino[2,3-*a*][1,2,4]triazine-5(6*H*),9(8*H*),14(15*H*)-trione (11b).
The first chromatographic separation was performed with ethyl dichloromethane/ethyl acetate 1:1. The last fraction collected was purified in the next chromatographic separation using dichloromethane/methanol 10:1 v/v as the eluent to afford the desired cycloadduct.

Yellow solid, yield 20%, 180 mg, mp (dec.) 182–184; IR (v_{max}, cm^{-1}): 3070, 3037, 2881, 1706 (C=O), 1683 (C5=O), 1660 (C=N), 1473, 1451, 1320, 1132, 699. ^1H NMR (200 MHz, DMSO-d_6): δ_H 3.66–3.89 (4H, m, -CH_2–CH_2- imidaz.), 5.64–5.67 (1H, m, H7), 5.98 (d, *J* = 2.2 Hz, H6a), 6.63 (dt, 1H, *J* = 6.1, 1.5 Hz, H19), 7.20–7.31 (m, 2H, H16+1H aromat.), 7.36–7.41 (m, 1H, H18), 7.75 (d, 1H, *J* = 2.2 Hz, aromat.), 7.83 (dd, 1H, *J* = 8.5, ~1 Hz, aromat.), 7.92–7.97 (m, 2H, aromat.), 8.13–8.23 (m, 2H, aromat.). ^{13}C NMR (50 MHz, DMSO-d_6): δ_C 44.7 (C3), 48.8 (C2), 50.8 (C7), 58.4 (C10), 67.7 (C6a), 127.1, 127.28, 127.33, 127.97, 128.0, 128.9, 130.5, 313.3, 131.5, 131.9, 134.1, 134.2, 135.0, 137.5 (14C, aromat.+CH=CH), 148.6 (C=N), 150.8 (C5=O), 152.9, 153.7 (2×C=O of 2,3-dihydrophthalazine-1,4-dione). Anal. Calcd for $C_{23}H_{16}Cl_2N_6O_3$ (495.32): C, 55.77; H, 3.26; N, 16.97%. Found: C, 55.61; H, 3.22; N, 16.92%.

X-ray crystal structure analysis. The diffraction data for single crystals of compound **6** were collected at 130K with Oxford Diffraction XCaliburE diffractometer using Mo Kα radiation and those of compound **9b** at 293K with an Oxford Diffraction SuperNova diffractometer using Cu Kα radiation. The intensity data were collected and processed using CrysAlisPro Software. The structures were solved by direct methods with the program SHELXS-97[29] and refined by full-matrix least-squares method on F^2 with SHELXL-97.[29] Crystallographic data for compounds **6** and **9b** have been deposited in the Cambridge Crystallographic Data Centre, with the deposition Nos CCDC 814026 & 814027.

Crystal data for **6**: $C_{19}H_{18}N_8O_2 \cdot C_6H_6 \cdot H_2O$, monoclinic, space group *C2/c*, $a = 28.1800(9)$, $b = 9.5506(3)$, $c = 19.5038(7)$ Å, $\beta = 117.485(4)°$, $V = 4656.7(3)$ Å^3, $Z = 8$, $T = 130$ K, $d_x = 1.388$ g cm^{-3}, μ(Mo Kα) = 0.096 mm^{-1}, 13385 data were collected up to $\theta_{max} = 26.37°$ ($R_{int} = 0.0191$, $R_\sigma = 0.0285$). Final R indices for 3660 reflections with $I > 2\sigma(I)$ and 334 refined parameters are: $R_1 = 0.0388$, $wR_2 = 0.1047$ ($R_1 = 0.0511$, $wR_2 = 0.1082$ for all 4741 data). Water molecule is disordered over two sites with equal occupancies.

Crystal data for **9b**: $C_{23}H_{20}ClN_7O_3$, orthorhombic, space group *Pbca*, $a = 14.5913(2)$, $b = 7.9820(1)$, $c = 36.2167(4)$ Å, $V = 4218.08(9)$ Å^3, $Z = 8$, $T = 293$ K, $d_x = 1.505$ g cm^{-3}, μ(Cu Kα)=1.981 mm^{-1}, 61573 data were collected up to $\theta_{max} = 73.83°$ ($R_{int} = 0.0321$, $R_\sigma = 0.0096$). Final R indices for 4071 reflections with $I > 2\sigma(I)$ and 308 refined parameters are: $R_1 = 0.0344$, $wR_2 = 0.0957$ ($R_1 = 0.0353$, $wR_2 = 0.0965$ for all 4237 data).

Cytotoxic activity. All cell lines were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ) (Braunschweig, Germany). Cytotoxicity studies were performed with a well-established microtiter assay based on the staining of adherent cells with crystal violet; the method has been described in detail in previous publications.[25] DMSO stock solutions of the compounds were diluted 1000-fold in cell culture medium (RPMI 1640 medium supplemented with 10% fetal calf serum) to give the final test concentration. Five, 2-fold dilutions of test substance where used in each experiment (i.e., 20, 10, 5.0, 2.5, 1.25 µM). Untreated controls received only DMSO (0.1%). Cells were continuously exposed to compounds for 96 h at 37 ºC in a humid atmosphere of 5% CO_2/air. The IC$_{50}$ values were estimated by least squares analysis of the dose-response curves to give the concentration of substance that inhibits cell growth by 50% compared to untreated controls. Reported IC$_{50}$ values are the averages of 3–6 independent determinations.

Acknowledgements

References

1. (a) Toyoda, T.; Brobey, R. K. B.; Sano, G.-I.; Horii, T.; Tomioka, N.; Itai, A. *Biochem. Biophys. Res. Comm.* **1997**, *235*, 515. (b) Itai, A., Toyoda, T. Japanese Patent 10 310 526, 1998; *Chem. Abstr.* **1999**, *130*, 62956. (c) Gulyás, G.; Emri, T.; Simon, A.; Györgydeák, Z. *Folia Microbiol. (Praha)* **2002**, *47*, 29. (d) Dolzhenko, A. V.; Chui, W.-K.; Dolzhenko, A. V.; Chan, L.-W. *J. Fluor. Chem.* **2005**, *126*, 795. (e) Dolzhenko, A. V.; Chui, W.-K. *J. Heterocycl. Chem.* **2006**, *43*, 95. (f) Dolzhenko, A. V., Chui, W.-K., Dolzhenko, A. V. *J. Heterocycl. Chem.* **2006**, *43*, 1513.

2. Novellino, E.; Abignete, E.; Cosimelli, B.; Greco, G.; Iadanza, M.; Laneri, S.; Lavecchia, A.; Rimoli, M. G. *J. Med. Chem.* **2002**, *45*, 5030.

3. (a) Kim, S.-H.; Bartholomew, D. G.; Allen L. B. *J. Med. Chem.* **1978**, *21*, 883. (b) Golankiewicz, B.; Januszczyk, P.; Ikeda, S.; Balzarini, J.; De Clerq, E. *J. Med. Chem.* **1995**, *38*, 3558. (c). Ojwang, J. O; Ali, S.; Smee, D. F.; Morrey, J. D.; Shimasaki, C. D.; Sidwell, R. W. *Antiviral Res.* **2005**, *68*, 49. (d) Dukhan, D.; Leroy, F.; Peyronnet, J.; Bosc, E.; Chaves, D.; Durka, M.; Storer, R.; La Colla, P.; Gosselin, G. *Nuclosides, Nuclotides and Nucleic Acids* **2005**, *24*, 671.

4. Luengo, J. I.; Duffy, K. J. US Patent 6 346 531 B1, 2002.

5. (a) Heider, J.; Austel, V.; Hanel, N.; Noll, K. *et al.*, Ger. Pat. 3 443 812, 1986; *Chem. Abstr.* **1986**, *105*, 153064k. (b) Sączewski, F.; Nasal, A. *Acta Pol. Pharm. – Drug Research* **1993**, *50*, 337. (c) Sączewski, F.; Nasal, A. *Acta Pol. Pharm. – Drug Research* **1995**, *52*, 237.

6. Heider, J.; Austel, V.; Hanel, N.; Noll, K. *et al.* Ger. Pat. 346 778, 1986; C*hem. Abstr.* **1986**, *105*, 172459j.

7. Matosiuk, D. M.; Fidecka, S.; Antkiewicz-Michaluk, L.; Lipkowski, J.; Dybała, I.; Kozioł, A. E. *Eur. J. Med. Chem.* **2002**, *37*, 761.

8. (a) Bekircan, O.; Küxük, M.; Kahveci, B.; Kolayli S. *Arch. Pharm. Chem. Life Sci.* **2005**, *338*, 365. (b) Łakomska, I.; Golankiewicz, B.; Wietrzyk, J.; Pełczyńska, M.; Nasulewicz, A.; Opolski, A.; Sitkowski, J.; Kozerski, L.; Szłyk, E. *Inorg. Chim. Acta.* **2005**, *358*, 1911. c) Sączewski, F.; Maruszak, M.; Bednarski, P. J. *Arch. Pharm. Chem. Life Sci.* **2008**, *341*, 121.

9. Sączewski, F.; Foks, H. *Synthesis* **1981**, 154.

10. Sączewski, F.; Gdaniec, M.; Ośmiałowski, K. *J. Chem. Soc, Perkin Trans. 1* **1987**, 1033.

11. (a) Schenker, K.; Druey, J. *Helv. Chim. Acta* **1959**, *42*, 1971. (b) Buchi, G.; Coffen, D. L.; Kocsis, K.; Sonnet, P. E.; Ziegler, F. E. *J. Am. Chem. Soc.* **1965**, *87*, 2073. (c) Weinstein, B.; Chang Lin, L.-Ch.; Fowler, F. W. *J. Org. Chem.* **1980**, *45*, 1657. (d) Sundberg, R. J.; Bloom, J. D. *J. Org. Chem.* **1980**, *45*, 3382. (e) Sundberg, R. J.; Bloom, J. D. *J. Org. Chem.* **1981**, *46*, 4863. (e) Buchi, G.; Coffen, D. L.; Kocsis, K.; Sonnet, P. E.; Ziegler, F. E. *J. Am. Chem. Soc.* **1996**, *88*, 2532. (g) Nakano, H.; Tsugawa, N.; Takahashi, K.; Okuyama, Y.; Fujita, R. *Tetrahedron* **2006**, *62*, 10879. (h) Nakano, H.; Tsugawa, N.; Fujita, R. *Tetrahedron Lett.* **2005**, *46*, 5677.

12. (a) Tomisawa, H.; Hongo, H., *Tetrahedron Lett.* **1969**, *29*, 2465. (b) Mariano, P. S.; Huesmann, P. L.; Beamer, R. L.; Dunaway-Mariano, D. *Tetrahedron*, **1978**, *34*, 2617. (c) Tomisawa, H.; Nakano, H.; Hongo, H. *Heterocycles* **1990**, *30*, 359. (d) Posner, G. H.; Vinader, V.; Afarinkia, K. *J. Org. Chem*. **1992**, *57*, 4088. (e) Afarinkia, K.; Mahmood, F. *Tetrahedron Lett.* **1998**, *39*, 493.

13. Tomisawa, H.; Nakano, H.; Hongo, H. *Chem. Pharm. Bull.* **1988**, *36*, 1692.

14. iboga alkaloids: (a) Popik, P.; Layer, R. T.; Skolnick, P. *Pharmcol. Rev.* **1995**, *47*, 235. (b) Popik, P.; Glick, S. D. *Drugs Future* **1996**, *21*, 1109. (c) Popik, P. *Life Sciences* **1996**, *59*, PL-379. (d) Popik, P.; Layer, R. T.; Skolnick, P. in *The Alkaloids*, Cordell, G.A. Ed.; Academic Press: San Diego, 1998; Vol. 52, pp 197–231. (e) Levi, M. S.; Borne, R. F. *Curr. Med. Chem.* **2002**, *9*, 1807. (f) He, D.-Y.; McGough, N. N. H.; Ravindranathan, A.; Jeanblanc, J.; Logrip, M. L.; Phamloung, K.; Janak, P. H.; Ron, D. *J. Neurosc.* **2005**, *25*, 619. (g) Sundberg, R. J.; Smith, S. Q. in *The Alkaloids*, Cordell, G.A. Ed.; Elsevier, 2002, Vol. 59, pp 281–376. dioscorine: (h) Broadbent, J. L.; Schnieden, H. *Br. J. Pharamcol.* **1958**, *13*, 213. (h) Nagata, K.; Aistrup, G. L.; Honda, H.; Shono, T.; Narahashi, T. *Pestic. Biochem. Physiol.* **1999**, *64*, 157.

15. Iwu, M. M.U. S. Patent 5 019 580, 1991; *Chem. Abstr.* **1992**, *116*, 76378.

16. (a) Khan, M.O. F.; Levi, M. S.; Clark, C. R.; Ablordeppey, S. Y.; Law, S.-J.; Wilson, N. H.; Borne, R. F. in *Studies in Natural Products Chemistry*, ur-Rahman, A. Ed.; Elsevier, 2008, Vol. 34, pp 753–787. (b) Iriepa, I.; Villasante, F. J.; Gálvez, E.; Labeaga, L.; Innerarity, A.; Orjales, A. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 189. (c) Tomiyama, T.; Tomiyama, A.; Imamaki, T.; Ueyama, N.; Sonegawa, M.; Takeuchi, S. U. S. Pat. 6 124 460, 2000; *Chem. Abstr.* **2000**, *133*, 17677p. (d) Yonan, P. K. U. S. Pat. 4 134 890, 1979. (e) Scherico Ltd., U. S. Pat. 1 095 105, 1965; *Chem. Abstr.* **1967**, *66*, 37787a. (f) Plumpe, H.; Puls, W. U. S. Pat. 3 764 605, 1973. (g) Tomiyama, H.; Kobayashi, Y.; Noda, A.U. S. Pat. 6 903 111 B2, 2005. (h) Villani, F. J. Canadian Pat. CA 828 738, 1969; *Chem. Abstr.* **1969**, *71*, 124281c. (i) Bernardi, L.; Bertazzoli, C.; Chieli, T.; Maggioni, P.U. S. Pat. 3 709 893, 1973. (j) Yokota, M.; Takizawa, E.; Ohkura, Y.; Fukai, C.; Tomiyama, T. *Eur. J. Med. Chem.* **1997**, *32*, 377. (k) Adelstein, G. W.; Yen, Ch. H.; Dajani, E. Z.; Bianchi, R. G. *J. Med. Chem.* **1976**, *19*, 1221. (l) Adelstein, G. W. U. S. Pat. 4 028 364, 1977; *Chem. Abstr.* **1977**, *87*, 84848q. (m) Pfizer inc. Eur. Pat. Appl. 0 356 193 A2, 1989. (n) Khan, M. O. F.; Levi, M. S.; Tekwani, B. L.; Wilson, N. H., Borne, R. F. *Bioorg. Med. Chem.* **2007**, *15*, 3919.

17. (a) Matsumara, Y.; Nakamura, Y.; Maki, T; Onomura, O. *Tetrahedron Lett.* **2000**, *41*, 7685. (b) Takenaka, N.; Huang, Y.; Rawal, V. H. *Tetrahedron Lett.* **2002**, *58*, 8299; (c) Hirama, M.; Kato, Y.; Seki, Ch.; Matsuyama, H.; Oshikiri, N.; Iyoda, M. *Chem. Lett.* **2008**, *37*, 924.

18. (a) Sauer, J.; Sustmann, R. *Angew. Chem. Int. Ed. Engl.* **1980**, *19*, 779. (b) Pindur, U.; Lutz, G.; Otto, Ch. *Chem. Rev.* **1993**, *93*, 741.

19. (a) Knaus, E. E.; Pasutto, F. M.; Giam, C. S. *J. Heterocycl. Chem.* **1974**, *11*, 843. (b) Knaus, E. E.; Pasutto, F. M.; Giam, C. S.; Swinyard, E. A. *J. Heterocycl. Chem.* **1976**, *13*, 481. (c) Kane, V. V.; Werblood, H.; Levine, S. D. *J. Heterocycl. Chem.* **1976**, *13*, 673. (d) Knaus, E.

E.; Redda, K. *Can. J. Chem.* **1977**, *55*, 1788. (e) Shusherina, N. P.; Said, M.; Likhomanova, T. I. *Zh. Org. Khim.* **1978**, *14*, 841. (f) Gazzaeva, R. A.; Drebenkowa, L. V.; Likhomanova, T. I.; Zyk, N. V. *Chem. Heterocycl. Comp.* **1997**, *33*, 596.

20. Levine, S.; Kane, V. V. U. S. Patent 4 057 547, 1977; *Chem. Abstr.* **1977**, *87*, 152222h.

21. (a) Tori, K; Hata, Y.; Muneyuki, R.; Takano, Y.; Tsuji, T.; Tanida, H. *Can. J. Chem.* **1964**, *42*, 926. (b) Tomisawa, H.; Fujita, R.; Noguchi, K.; Hongo, H. *Chem. Pharm. Bull.* **1970**, *18*, 941.

22. Haukaas, M. H.; O'Doherty, G. A. *Org. Lett.* **2002**, *4*, 1771.

23. Bondi, A. *J. Phys. Chem.* **1964**, *68*, 441.

24. Clement, R. A. *J. Org. Chem.* **1960**, *25*, 1724.

25. In vitro cytotoxic activity was tested according to the procedure described in: Bracht, K.; Boubakari, Grünert, R.; Bednarski, P. J. *Anticancer Drugs* **2006**, *17*, 41.

26. (a) Brum-Bousquet, M.; Mitkau, S.; Skaltsounis, A.-L.; Tillequin, F.; Koch, M. *Planta Med.* **1988**, *54*, 470. (b) Thi Mai, H. D.; Gaslonde, T.; Michel, S.; Tillequin, F.; Koch, M.; Bongui, J. B.; Elmori, A.; Seguin, E.; Pfeiffer, B.; Renard, P.; David-Cordonnier, M. H.; Laine, W.; Bailly, C.; Kraus-Berthier, L.; Léonce, S.; Hickman, J. A.; Pierré, A. *J. Med. Chem.* **2003**, *46*, 3072.

27. Triani, A.; Bellasio, E. *J. Heterocycl. Chem.* **1974**, *11*, 257.

28. Myers, A. G.; Zheng, B.; Movassaghi, M. *J. Org. Chem.* **1997**, *62*, 7507.

29. Sheldrick, G. M. *Acta Cryst.* **2008**, *A64*, 112.